Inhaled Amikacin: Can It Prevent Ventilator Pneumonia?

Why do CDC's COVID-19 findings matter for pneumonia prevention?

CDC's COVID-19 and antimicrobial resistance review, updated in February 2025, describes an earlier pandemic setback rather than a newly announced October finding. Among seven resistant pathogens, hospital-onset infections and deaths each increased by at least 15% from 2019 to 2020. CDC identifies several contributing pressures, including more severely ill patients, prolonged use of ventilators and catheters, staffing shortages and disrupted prevention practices. [CDC pandemic assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

Ventilator-associated pneumonia is one target for prevention because it can prolong intensive care and increase antimicrobial treatment. Professional guidance also notes that distinguishing bacterial superinfection from underlying COVID-19 lung disease can be difficult: fever, worsening oxygenation and abnormal imaging may overlap. Preventive strategies therefore need evaluation against meaningful patient outcomes, alongside careful infection diagnosis. [Hospital pneumonia prevention guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC10903147/)

What did studies find about preventive inhaled amikacin?

The AMIKINHAL trial, published in the New England Journal of Medicine in 2023, studied adults ventilated for at least 72 hours. Participants received inhaled amikacin or placebo once daily for three days. By day 28, pneumonia occurred in 62 of 417 patients receiving amikacin and 95 of 430 receiving placebo—approximately 15% versus 22%. [AMIKINHAL trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2310307)

Delivering antibiotics into the airways aims to achieve high local concentrations before pneumonia develops. Administration nevertheless carries risks: trial-related serious adverse effects occurred in seven amikacin recipients and four placebo recipients, including airway or ventilator-circuit complications. [Trial safety findings](https://www.nejm.org/doi/full/10.1056/NEJMoa2310307)

A separate study published in December 2025 reviewed 66 ventilated trauma patients at one hospital. After statistical adjustment, researchers found no significant association between preventive amikacin and pneumonia risk. Because treatment was not randomly assigned and the sample was small, this study cannot overturn the randomized evidence or establish that the drug has no effect. It does raise questions about how reliably the benefit transfers to different ICU populations. [Trauma ICU cohort study](https://pubmed.ncbi.nlm.nih.gov/41492902/)

Could preventive antibiotics help control resistance?

The central clinical question is whether a short preventive course produces enough benefit to justify additional antibiotic exposure. CDC emphasizes that antimicrobial use can contribute to resistance and that preventing infections is essential. The inference for inhaled prevention is that fewer pneumonias might mean fewer later treatments; that possibility should not be presented as proof that this strategy reduces antimicrobial resistance. [CDC resistance assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

Established prevention measures remain essential. The 2022 guidance led by the Society for Healthcare Epidemiology of America recommends minimizing sedation, using protocols to help patients leave mechanical ventilation when ready, elevating the head of the bed when appropriate, and providing oral care with toothbrushing. This guidance predates AMIKINHAL, so it provides a foundation for prevention rather than an assessment of that later trial. Families can ask how these measures are incorporated into an individual patient's care. [SHEA-led prevention guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC10903147/)

The trauma cohort also illustrates why implementation deserves scrutiny. Baseline illness severity differed between groups, and the investigators could not fully assess factors such as sedation and ventilator settings. Further studies need to clarify which patients benefit and whether any reduction in pneumonia translates into better recovery without unacceptable harms. [Study limitations](https://pubmed.ncbi.nlm.nih.gov/41492902/)